A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer

2011153 citationsJournal Article

Authors

E. David Crawford · University of Colorado Denver

Bertrand Tombal · Cliniques Universitaires Saint-Luc

Kurt Miller · Charité - Universitätsmedizin Berlin

L Boccon-Gibod · Université Claude Bernard Lyon 1

Fritz H. Schröder · Erasmus MC

Neal D. Shore · Carolina Urologic Research Center

Judd W. Moul

Abstract

Data support the statistically significant prostate specific antigen progression-free survival benefit for degarelix over leuprolide seen during year 1 and the use of degarelix as first line androgen deprivation therapy as an alternative to a gonadotropin-releasing hormone agonist.

Topics & Keywords

Prostate Cancer Treatment and Research Cancer, Lipids, and Metabolism Hormonal and reproductive studies

Publication Details

Published in: The Journal of Urology

Volume 186, Issue 3, pp. 889-897

DOI: 10.1016/j.juro.2011.04.083

Field-Weighted Citation Impact: 15.71

Command Palette

A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer

Authors

Abstract

Topics & Keywords

Publication Details